These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

916 related items for PubMed ID: 16523251

  • 1. Comorbid oppositional defiant disorder and the risk of relapse during 9 months of atomoxetine treatment for attention-deficit/hyperactivity disorder.
    Hazell P, Zhang S, Wolańczyk T, Barton J, Johnson M, Zuddas A, Danckaerts M, Ladikos A, Benn D, Yoran-Hegesh R, Zeiner P, Michelson D.
    Eur Child Adolesc Psychiatry; 2006 Mar; 15(2):105-10. PubMed ID: 16523251
    [Abstract] [Full Text] [Related]

  • 2. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
    Dittmann RW, Schacht A, Helsberg K, Schneider-Fresenius C, Lehmann M, Lehmkuhl G, Wehmeier PM.
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):97-110. PubMed ID: 21488751
    [Abstract] [Full Text] [Related]

  • 3. Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data.
    Biederman J, Spencer TJ, Newcorn JH, Gao H, Milton DR, Feldman PD, Witte MM.
    Psychopharmacology (Berl); 2007 Jan; 190(1):31-41. PubMed ID: 17093981
    [Abstract] [Full Text] [Related]

  • 4. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
    Dell'Agnello G, Maschietto D, Bravaccio C, Calamoneri F, Masi G, Curatolo P, Besana D, Mancini F, Rossi A, Poole L, Escobar R, Zuddas A, LYCY Study Group.
    Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder.
    Kaplan S, Heiligenstein J, West S, Busner J, Harder D, Dittmann R, Casat C, Wernicke JF.
    J Atten Disord; 2004 Oct; 8(2):45-52. PubMed ID: 15801334
    [Abstract] [Full Text] [Related]

  • 6. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
    Bangs ME, Hazell P, Danckaerts M, Hoare P, Coghill DR, Wehmeier PM, Williams DW, Moore RJ, Levine L, Atomoxetine ADHD/ODD Study Group.
    Pediatrics; 2008 Feb; 121(2):e314-20. PubMed ID: 18245404
    [Abstract] [Full Text] [Related]

  • 7. Does Comorbid Disruptive Behavior Modify the Effects of Atomoxetine on ADHD Symptoms as Measured by a Continuous Performance Test and a Motion Tracking Device?
    Wehmeier PM, Kipp L, Banaschewski T, Dittmann RW, Schacht A.
    J Atten Disord; 2015 Jul; 19(7):591-602. PubMed ID: 22930789
    [Abstract] [Full Text] [Related]

  • 8. Relationship between atomoxetine plasma concentration, treatment response and tolerability in attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder.
    Hazell P, Becker K, Nikkanen EA, Trzepacz PT, Tanaka Y, Tabas L, D'Souza DN, Witcher J, Long A, Ponsler G, Dittmann RW.
    Atten Defic Hyperact Disord; 2009 Dec; 1(2):201-10. PubMed ID: 20234828
    [Abstract] [Full Text] [Related]

  • 9. Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder.
    Newcorn JH, Spencer TJ, Biederman J, Milton DR, Michelson D.
    J Am Acad Child Adolesc Psychiatry; 2005 Mar; 44(3):240-8. PubMed ID: 15725968
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis.
    Cheng JY, Chen RY, Ko JS, Ng EM.
    Psychopharmacology (Berl); 2007 Oct; 194(2):197-209. PubMed ID: 17572882
    [Abstract] [Full Text] [Related]

  • 11. Effect of atomoxetine on quality of life and family burden: results from a randomized, placebo-controlled, double-blind study in children and adolescents with ADHD and comorbid oppositional defiant or conduct disorder.
    Wehmeier PM, Schacht A, Dittmann RW, Helsberg K, Schneider-Fresenius C, Lehmann M, Bullinger M, Ravens-Sieberer U.
    Qual Life Res; 2011 Jun; 20(5):691-702. PubMed ID: 21136299
    [Abstract] [Full Text] [Related]

  • 12. Combination use of atomoxetine hydrochloride and olanzapine in the treatment of attention-deficit/hyperactivity disorder with comorbid disruptive behavior disorder in children and adolescents 10-18 years of age.
    Holzer B, Lopes V, Lehman R.
    J Child Adolesc Psychopharmacol; 2013 Aug; 23(6):415-8. PubMed ID: 23952189
    [Abstract] [Full Text] [Related]

  • 13. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.
    Harfterkamp M, van de Loo-Neus G, Minderaa RB, van der Gaag RJ, Escobar R, Schacht A, Pamulapati S, Buitelaar JK, Hoekstra PJ.
    J Am Acad Child Adolesc Psychiatry; 2012 Jul; 51(7):733-41. PubMed ID: 22721596
    [Abstract] [Full Text] [Related]

  • 14. Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder.
    Geller D, Donnelly C, Lopez F, Rubin R, Newcorn J, Sutton V, Bakken R, Paczkowski M, Kelsey D, Sumner C.
    J Am Acad Child Adolesc Psychiatry; 2007 Sep; 46(9):1119-1127. PubMed ID: 17712235
    [Abstract] [Full Text] [Related]

  • 15. A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder.
    Gau SS, Huang YS, Soong WT, Chou MC, Chou WJ, Shang CY, Tseng WL, Allen AJ, Lee P.
    J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):447-60. PubMed ID: 17822340
    [Abstract] [Full Text] [Related]

  • 16. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders.
    Wilens TE, Adler LA, Weiss MD, Michelson D, Ramsey JL, Moore RJ, Renard D, Brady KT, Trzepacz PT, Schuh LM, Ahrbecker LM, Levine LR, Atomoxetine ADHD/SUD Study Group.
    Drug Alcohol Depend; 2008 Jul 01; 96(1-2):145-54. PubMed ID: 18403134
    [Abstract] [Full Text] [Related]

  • 17. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 1: psychostimulants, alpha-2 agonists, and atomoxetine.
    Pringsheim T, Hirsch L, Gardner D, Gorman DA.
    Can J Psychiatry; 2015 Feb 01; 60(2):42-51. PubMed ID: 25886655
    [Abstract] [Full Text] [Related]

  • 18. Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension study.
    Harfterkamp M, Buitelaar JK, Minderaa RB, van de Loo-Neus G, van der Gaag RJ, Hoekstra PJ.
    J Child Adolesc Psychopharmacol; 2013 Apr 01; 23(3):194-9. PubMed ID: 23578015
    [Abstract] [Full Text] [Related]

  • 19. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial.
    Kelsey DK, Sumner CR, Casat CD, Coury DL, Quintana H, Saylor KE, Sutton VK, Gonzales J, Malcolm SK, Schuh KJ, Allen AJ.
    Pediatrics; 2004 Jul 01; 114(1):e1-8. PubMed ID: 15231966
    [Abstract] [Full Text] [Related]

  • 20. Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study.
    Troost PW, Steenhuis MP, Tuynman-Qua HG, Kalverdijk LJ, Buitelaar JK, Minderaa RB, Hoekstra PJ.
    J Child Adolesc Psychopharmacol; 2006 Oct 01; 16(5):611-9. PubMed ID: 17069549
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.